Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim safety analysis

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3546 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3546-3546

Author(s):

H.-T. Arkenau ◽

H. Schmoll ◽

S. Kubicka ◽

T. Seufferlein ◽

P. Reichardt ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Safety Analysis ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Advanced Colorectal Carcinoma ◽

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3546 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3546-3546 ◽

Cited By ~ 1

Author(s):

H.-T. Arkenau ◽

H. Schmoll ◽

S. Kubicka ◽

T. Seufferlein ◽

P. Reichardt ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Safety Analysis ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Advanced Colorectal Carcinoma ◽

Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3516 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3516-3516 ◽

Cited By ~ 7

Author(s):

A. Schalhorn ◽

F. W. Ludwig ◽

D. Quietzsch ◽

P. A. Maubach ◽

G. Schlimok ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer

European Journal of Cancer ◽

10.1016/j.ejca.2010.09.022 ◽

2011 ◽

Vol 47 (2) ◽

pp. 206-214 ◽

Cited By ~ 30

Author(s):

Ludwig Fischer von Weikersthal ◽

Andreas Schalhorn ◽

Martina Stauch ◽

Detlef Quietzsch ◽

Peter A. Maubach ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Advanced Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Acid Versus ◽

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

British Journal of Cancer ◽

10.1038/sj.bjc.6603011 ◽

2006 ◽

Vol 94 (6) ◽

pp. 798-805 ◽

Cited By ~ 236

Author(s):

J Souglakos ◽

N Androulakis ◽

K Syrigos ◽

A Polyzos ◽

N Ziras ◽

...

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Research Group ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Oncology Research ◽

FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer

http://isrctn.org/> ◽

10.1186/isrctn83867919 ◽

2012 ◽

Author(s):

Ricky Sharma

Keyword(s):

Colorectal Cancer ◽

Folinic Acid ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The GEICAM/GBG Lea Study. Safety Analysis

Annals of Oncology ◽

10.1016/s0923-7534(20)32942-2 ◽

2012 ◽

Vol 23 ◽

pp. ix118

Author(s):

S. Loibl ◽

J.R. La De Haba ◽

G. von Minckwitz ◽

S. Morales ◽

C. Crespo ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Safety Analysis ◽

Advanced Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE ‐3 ( AIO KRK ‐0306)

International Journal of Cancer ◽

10.1002/ijc.33775 ◽

2021 ◽

Author(s):

Lian Liu ◽

Nicole Tonya Erickson ◽

Ingrid Ricard ◽

Ludwig Fischer Weikersthal ◽

Markus M. Lerch ◽

...

Keyword(s):

Colorectal Cancer ◽

Weight Loss ◽

Risk Factor ◽

Independent Risk Factor ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Early Weight Loss ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group

Annals of Oncology ◽

10.1093/annonc/mdx122 ◽

2017 ◽

Vol 28 (6) ◽

pp. 1288-1293 ◽

Cited By ~ 25

Author(s):

J.J.M. Kwakman ◽

L.H.J. Simkens ◽

J.M. van Rooijen ◽

A.J. van de Wouw ◽

A.J. ten Tije ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Cancer Group ◽